UnitedHealth Group Incorporated (UNH) Guidance & Earnings Results

On 2026-10-13 UnitedHealth Group Incorporated raised guidance: "FY2026 GAAP EPS at least $19.50; adjusted EPS at least…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

UNHUnitedHealth Group IncorporatedFollow UNH — free

Healthcare Plans · Healthcare

—

Price chart with a free account

Market cap: 375.3B
P/E TTM: 26.9
Dividend yield: 2.1%
52-week: —
Next earnings: 25 Jan, in 93 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
13 Oct 26	Raised	FY2026 GAAP EPS at least $19.50; adjusted EPS at least $20.50 · full year
16 Jul 26	Raised	FY2026 adjusted net earnings per share raised to $19.50-$20.00 from prior range; FY2026 reported EPS $18.45-$18.95; FY2026 medical care ratio 88.1% ± 25 bps; FY2026 tax rate ~18.5%; FY2026 cash flows from operations ~$24B; FY2026 share repurchase at least $5B; FY2026 net earnings to UNH shareholders >$16.75B; FY2026 UnitedHealthcare operating earnings >$12B; FY2026 Optum Health operating earnings · full year
21 Apr 26	Raised	Raised full year 2026 adjusted EPS guidance to >$18.25 from >$17.35 · full year
27 Jan 26	Raised	FY2026 revenue >$439B, adj. EPS >$17.75, ops earnings >$24B · full year
28 Oct 25	Raised	FY2025 adjusted EPS at least $16.25 · full year
29 Jul 25	Reaffirmed	FY25 revenue $445.5-448.0B; net EPS at least $14.65; adjusted EPS at least $16.00; MCR 89.25% +/- 25 bps; operating cost ratio 12.75% +/- 25 bps; tax rate ~18.5% · full year

UnitedHealth Group Incorporated — questions

What guidance did UnitedHealth Group Incorporated give?: On 2026-10-13: "FY2026 GAAP EPS at least $19.50; adjusted EPS at least $20.50"
When does UnitedHealth Group Incorporated report earnings?: UnitedHealth Group Incorporated's next earnings report is expected on 2027-01-25.

Every figure on this page comes from UnitedHealth Group Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.